Stockreport

Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst [Seeking Alpha]

Alector, Inc.  (ALEC) 
Last alector, inc. earnings: 3/24 04:05 pm Check Earnings Report
PDF Nivisnebart, targeting Alzheimer's, is ALEC's next major catalyst; interim Phase 2 PROGRESS-AD data is expected early 2026. Both Nivisnebart and Latozinemab share a c [Read more]